{
    "ticker": "KRYS",
    "name": "Krystal Biotech, Inc.",
    "description": "Krystal Biotech, Inc. is a biotechnology company focused on developing innovative gene therapies for patients with rare diseases. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech harnesses the power of its proprietary Skin TAR\u2122 platform to create treatments that target genetic skin disorders. The company is particularly noted for its lead product candidate, KB103, which is designed to treat dystrophic epidermolysis bullosa (DEB), a serious genetic skin disease characterized by fragile skin that blisters easily. Krystal's approach involves the use of genetically modified viruses that deliver healthy copies of the gene responsible for skin integrity directly to the affected cells. The company is committed to advancing its pipeline of therapies while ensuring patient safety and efficacy through rigorous clinical trials. With a mission to transform the lives of patients suffering from rare diseases, Krystal Biotech is at the forefront of gene therapy innovation, aiming to provide hope and healing to those in need.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Pittsburgh, Pennsylvania, USA",
    "founded": "2015",
    "website": "https://www.krystalbio.com",
    "ceo": "Suma Krishnan",
    "social_media": {
        "twitter": "https://twitter.com/KrystalBiotech",
        "linkedin": "https://www.linkedin.com/company/krystal-biotech"
    },
    "investor_relations": "https://investors.krystalbio.com",
    "key_executives": [
        {
            "name": "Suma Krishnan",
            "position": "CEO"
        },
        {
            "name": "Rohit K. Bhatia",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "KB103"
            ]
        }
    ],
    "seo": {
        "meta_title": "Krystal Biotech, Inc. | Innovative Gene Therapies for Rare Diseases",
        "meta_description": "Explore Krystal Biotech, Inc., a leader in gene therapy focused on treating rare genetic skin disorders. Learn about their innovative platform and pipeline.",
        "keywords": [
            "Krystal Biotech",
            "Gene Therapy",
            "Dystrophic Epidermolysis Bullosa",
            "Biotechnology",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Krystal Biotech known for?",
            "answer": "Krystal Biotech is known for developing gene therapies for rare genetic skin diseases."
        },
        {
            "question": "Who is the CEO of Krystal Biotech?",
            "answer": "Suma Krishnan is the CEO of Krystal Biotech, Inc."
        },
        {
            "question": "Where is Krystal Biotech headquartered?",
            "answer": "Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, USA."
        },
        {
            "question": "What is KB103?",
            "answer": "KB103 is Krystal Biotech's lead product candidate aimed at treating dystrophic epidermolysis bullosa (DEB)."
        },
        {
            "question": "When was Krystal Biotech founded?",
            "answer": "Krystal Biotech was founded in 2015."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO",
        "NVTA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BMY"
    ]
}